Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
Wen-Xia Hu,Jing-Cui Peng,Yun Wang,Hao Jin,Nan Geng
DOI: https://doi.org/10.2147/IJGM.S350771
IF: 2.145
2022-04-27
International Journal of General Medicine
Abstract:Wen-Xia Hu, Jing-Cui Peng, Yun Wang, Hao Jin, Nan Geng Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People's Republic of China Correspondence: Nan Geng, Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, 12 Jian-Kang Road, Shijiazhuang, 050012, People's Republic of China, Tel +86 13933852787, Email Objective: This study was to investigate the efficacy and safety of gefitinib plus anlotinib for patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line setting. Methods: A total of 36 patients with previously-untreated EGFR positive advanced NSCLC were included in this study retrospectively. All patients were administered with gefitinib plus anlotinib combination therapy. The efficacy of the patients was evaluated with the change of target lesion using imaging evidence according to RECIST 1.1 criteria and all the patients were followed up regularly. Adverse reactions were collected and documented during the combination administration. Univariate analysis according to the baseline characteristic subgroup was implemented using Log rank test and multivariate analysis was adjusted by Cox regression analysis. Results: All the 36 patients included in our study were available for efficacy and safety analysis. Best overall response of the patients during gefitinib plus anlotinib administration suggested that partial response was observed in 30 patients, stable disease was noted in five patients, and progressive disease was found in one patient, which yielded an objective response rate (ORR) of 83.3% (95% CI=67.2– 93.6%) and a disease control rate (DCR) of 97.2% (95% CI=85.5– 99.9%). Prognostic data indicated that the median progression-free survival (PFS) of the 36 patients with NSCLC was 15.2 months (95% CI=8.15– 22.26). Furthermore, the median overall survival (OS) of the 36 patients was 35.9 months (95% CI=22.77– 49.03). Additionally, the most common adverse reactions of the patients with NSCLC were diarrhea (63.9%), fatigue (58.3%), hypertension (50.0%), rash (44.4%), and nausea and vomiting (41.7%). Furthermore, ECOG performance status was associated with PFS of gefitinib plus anlotinib combination therapy in baseline characteristic subgroup analysis. Conclusion: Gefitinib plus anlotinib regimen demonstrated encouraging efficacy and an acceptable safety profile for patients with previously untreated EGFR positive NSCLC preliminarily. The conclusion should be validated in prospective clinical trials subsequently. Keywords: non-small cell lung cancer, EGFR mutation, anlotinib, gefitinib, efficacy, safety As the second most common solid tumor and the leading cause of cancer-related death all over the world, lung cancer was observed of approximately 815,000 new cases and 715,000 deaths in China each year. 1 Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer. 2 Patients with epidermal growth factor receptor (EGFR) positive mutation were reported to be of almost 40% among all NSCLC in China. 3 As a result, it is estimated that there are approximately 277,000 new cases of NSCLC with EGFR positive mutation in China annually. To our knowledge, pivotal trials established EGFR tyrosine kinase inhibitor (TKI) therapy as the standard of care for patients with EGFR positive NSCLC since 2004. 4 Amazingly, recent years had witnessed remarkable achievements regarding the targeted drugs for patients with EGFR mutation, thus rendering NSCLC with a positive EGFR mutation the most successful cancer in precision medicine. 5 Gefitinib, erlotinib, afatinib, dacomitinib, and Osimertinib were efficacious in clinical practice as the first-line therapy for patients with EGFR mutation NSCLC currently. 6 Unfortunately, with regard to the first-generation EGFR TKIs (gefitinib, erlotinib, and Icotinib) in China, although 60–80% of the patients with EGFR positive mutation had responses following the administration with these drugs, the median progression-free survival (PFS) was still dismal (approximately 1 year) owing to the acquired therapeutic resistance. 7 Additionally, it should be noted that a third-generation EGFR TKI (Osimertinib) was a superior first-line treatment according to the FLAURA study. 8 However, there was no standard targeted drug therapy after Osimertinib progression and the optimized therapy strategy across multiple treatment lines remained unknown. 9 Consequently, it was necessary to investigate the efficacious first-generation EGFR TKI-based regimens for delaying the progression in the first-line setting urgently. Resistance to EGFR TKIs was always associated with elevated vascular endothelial -Abstract Truncated-
medicine, general & internal